Patent · US Expired

Beta-fluoroethyl thiourea compounds and use

US6300351A · kind A · utility

1Cited by

5References

12Claims

0Family size

Assignee

Parker Hughes Institute · US

Inventors

Rakesh Vig · Little Canada, US
Chen Mao · Shanghai, CN
Fatih A. Uckun · White Bear Lake, US

Key dates

Filing date	Oct 17, 2000
Grant date	Oct 9, 2001
Priority date	—
Expiry date	Oct 17, 2020

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D239/47
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel compounds that are potent inhibitors of HIV reverse transcriptase (RT) are described in the invention. These novel compounds also inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The novel compounds of the invention include analogs and derivatives of phenethylthiazolylthiourea (PETT), of dihydroalkoxybenzyloxopyrimidine (DABO), and of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). The invention additionally provides a composite HIV reverse-transcriptase (RT) nonnucleoside inhibitor (NNI) binding pocket constructed from a composite of multiple NNI-RT complexes The composite RT-NNI binding pocket provides a unique and useful tool for designing and identifying novel, potent inhibitors of reverse transcriptase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.